Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open randomized study of convalescent plasma for hospitalized COVID-19 patients with respiratory compromise
MOH_2020-12-13_009554Phase 3Not yet recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Need for mechanical ventilation and/or death by day 30. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2020-12-13_009554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-13_009554.